{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T22:35:52Z","timestamp":1791758152320,"version":"4.3.4"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:p>The aim of the present study was to evaluate the efficiency and side effects of mifamurtide in childhood osteosarcoma (OS). In total, 477 doses of 2\u2009mg\/m<jats:sup>2<\/jats:sup> intravenous (IV) mifamurtide, along with paracetamol as a premedication, were given to 15 patients with primary nonmetastatic OS after complete surgical resection and to 3 patients with progressive OS. The most common side effects encountered in the patients were chills and fever (17\/18). These reactions were observed in 4 patients during the administration of each dose, in a single patient during the last administration, and in the remaining 12 patients during the first or initial 2 administrations. Headache, myalgia, and arthralgia were observed in 2 patients during each infusion. Headache was observed in 1 patient with additional hearing loss during the first 2 infusions. One patient had back pain occuring within the first infusion. Of the 15 patients with primary nonmetastatic OS and treated with the addition of mifamurtide to chemotherapy, 13 showed a complete remission, and 2 patients were still under treatment with a complete remission. Of 3 patients with progressive disease, 2 died while the disease progressed further in the third case over a 51-month period. The 3-year overall survival and event-free survival distributions were 87.5% (mean follow-up time, 46.12; 95% confidence interval, 37.79-52.45\u2009mo) and 75.6% (mean follow-up time, 31.30; 95% confidence interval, 26.54-36.06\u2009mo), respectively. We consider that mifamurtide therapy is a safe and well-tolerated agent in childhood OS.<\/jats:p>","DOI":"10.1097\/mph.0000000000001236","type":"journal-article","created":{"date-parts":[[2018,6,10]],"date-time":"2018-06-10T15:33:08Z","timestamp":1528644788000},"page":"e373-e376","source":"Crossref","is-referenced-by-count":15,"title":["The Efficiency and Toxicity of Mifamurtide in Childhood Osteosarcoma"],"prefix":"10.1097","volume":"40","author":[{"given":"Nurdan","family":"Tacyildiz","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Oncology, Faculty of Medicine, Ankara University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonay","family":"Incesoy Ozdemir","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Oncology, Faculty of Medicine, Yildirim Beyazit University, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emel","family":"Unal","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Oncology, Faculty of Medicine, Ankara University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melda","family":"Berber","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Oncology, Faculty of Medicine, Ankara University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Handan","family":"Dincaslan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Oncology, Faculty of Medicine, Ankara University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulsan","family":"Yavuz","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Oncology, Faculty of Medicine, Ankara University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230918","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11864-017-0464-2","article-title":"Osteogenic sarcoma: systemic chemotherapy options for localized disease","volume":"18","author":"Harrison","year":"2017","journal-title":"Curr Treat Options Oncol"},{"key":"R2-20230918","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40744-016-0046-y","article-title":"Review of osteosarcoma and current management","volume":"3","author":"Durfee","year":"2016","journal-title":"Rheumatol Ther"},{"key":"R3-20230918","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/cncr.11799","article-title":"Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy","volume":"98","author":"Hawkins","year":"2003","journal-title":"Cancer"},{"key":"R4-20230918","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/978-3-319-53156-4_6","article-title":"Immune therapy for sarcomas","volume":"995","author":"Anderson","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2147\/TCRM.S5688","article-title":"Review of mifamurtide in the treatment of patients with osteosarcoma","volume":"6","author":"Kager","year":"2010","journal-title":"Ther Clin Risk Manag"},{"key":"R6-20230918","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2165\/11204910-000000000-00000","article-title":"Mifamurtide: a review of its use in the treatment of osteosarcoma","volume":"12","author":"Frampton","year":"2010","journal-title":"Paediatr Drugs"},{"key":"R7-20230918","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1358\/dot.2010.46.5.1500076","article-title":"Mifamurtide in osteosarcoma\u2014a practical review","volume":"46","author":"Anderson","year":"2010","journal-title":"Drugs Today (Barc)"},{"key":"R8-20230918","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1517\/14656566.2011.543129","article-title":"Mifamurtide for the treatment of nonmetastatic osteosarcoma","volume":"12","author":"Ando","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"R9-20230918","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/pbc.24686","article-title":"Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments","volume":"61","author":"Anderson","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"R10-20230918","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1517\/14656566.2015.1102226","article-title":"An update on chemotherapy for osteosarcoma","volume":"16","author":"Ferrari","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"R11-20230918","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1586\/14737140.8.2.151","article-title":"Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases","volume":"8","author":"Mori","year":"2008","journal-title":"Expert Rev Anticancer Ther"},{"key":"R12-20230918","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1200\/JCO.2008.14.0095","article-title":"Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival\u2014a report from the Children\u2019s Oncology Group","volume":"26","author":"Meyers","year":"2008","journal-title":"J Clin Oncol"},{"key":"R13-20230918","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jval.2013.08.2294","article-title":"Mifamurtide for high-grade, resectable, nonmetastatic osteosarcoma following surgical resection: a cost-effectiveness analysis","volume":"16","author":"Johal","year":"2013","journal-title":"Value Health"},{"key":"R14-20230918","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jval.2014.08.1662","article-title":"Economic considerations on the use of mifamurtide in the treatment of osteosarcoma in Spain","volume":"17","author":"Brosa","year":"2014","journal-title":"Value Health"},{"key":"R15-20230918","first-page":"492","article-title":"Initial clinical trial of the macrophage activator muramyl tripeptide-phosphotidylethanolamine encapsulated in lipsomes in patients with advanced cancer","volume":"9","author":"Creaven","year":"1990","journal-title":"J Biol Response Modif"},{"key":"R16-20230918","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1200\/JCO.1989.7.12.1915","article-title":"Phase I trial of liposomal muramyl tripeptide phosphotidylethanolamine in cancer patients","volume":"7","author":"Murray","year":"1989","journal-title":"J Clin Oncol"},{"key":"R17-20230918","doi-asserted-by":"crossref","first-page":"5339","DOI":"10.1002\/cncr.24566","article-title":"Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children\u2019s Oncology Group","volume":"115","author":"Chou","year":"2009","journal-title":"Cancer"},{"key":"R18-20230918","doi-asserted-by":"crossref","first-page":"6773","DOI":"10.1007\/s13277-015-3405-3","article-title":"Lifetime effectiveness of mifamurtide addition to chemotherapy in nonmetastatic and metastatic osteosarcoma: a Markov process model analysis","volume":"36","author":"Song","year":"2015","journal-title":"Tumour Biol"},{"key":"R19-20230918","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/978-3-319-04843-7_17","article-title":"Muramyl tripeptide-phosphatidyl ethanolamine encapsulated in liposomes (L-MTP-PE) in the treatment of osteosarcoma","volume":"804","author":"Meyers","year":"2014","journal-title":"Adv Exp Med Biol"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00043426-201808000-00029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T04:18:02Z","timestamp":1695010682000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00043426-201808000-00029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000001236","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]}}}